Novo Nordisk A/s

This study is testing a new medicine called concizumab to see if it can safely prevent bleeding episodes in people with haemophilia A or B. Participants will give themselves a daily injection at home and track their bleeds in a diary. The goal is to see if this daily treatment wo…

This study aims to understand how the medication Wegovy works for weight management when used in everyday medical practice, not in a controlled trial. It will follow about 1,250 adults with obesity for two years, tracking their weight, health measures, and quality of life as thei…

This study aims to understand how consistently following a prescribed growth hormone treatment plan affects how tall children grow. It will follow up to 750 children and teenagers in Germany who are starting treatment for growth hormone deficiency or who were born small for their…

This study is testing whether a new weekly injection called CagriSema helps people with excess body weight lose more weight than a placebo (dummy medicine) or the individual drugs alone. About 3,400 adults with obesity or overweight with a related health condition will receive in…

This is an early-stage study to test the safety and body processing of a new injectable medicine for people with overweight or obesity. Participants will receive either the new medicine or a placebo injection, and researchers will monitor for side effects. The main goal is to see…

This study is testing a new investigational weekly injection called CagriSema against an existing medication, tirzepatide, in adults with type 2 diabetes. The goal is to see which drug works better at lowering blood sugar levels and reducing body weight for people whose diabetes …

This study is testing whether a new weekly injection called CagriSema works better than an existing medication called tirzepatide for people with type 2 diabetes. About 1,000 participants whose diabetes isn't well controlled on current pills will receive either CagriSema or tirze…

This large, late-stage study is testing whether a weekly injection of semaglutide can help control and improve a serious fatty liver disease called NASH. About 1,200 adults with NASH will receive either the real medication or a placebo for up to five years to see if it can resolv…

This study is testing a new, long-acting growth hormone called somapacitan that children would receive just once a week. Researchers want to see if it works as well and is as safe as a standard daily growth hormone injection (Norditropin®). The trial includes 412 children with sh…

This study is testing the long-term safety and effectiveness of a weekly injection called semaglutide for weight management in children and adolescents aged 6 to 18 with obesity or overweight. Over 200 participants will receive either the active medication or a placebo injection …

This study is testing if a drug called etavopivat can improve blood flow and oxygen delivery to the brain in children and young adults with sickle cell disease. It will involve about 12 participants aged 12 to 21 who will take the drug for 24 weeks. Researchers will use special l…

This study is testing the long-term safety and effectiveness of a new medicine called Mim8 for people with haemophilia A. Mim8 is designed to prevent bleeding episodes by helping the blood to clot. The study will follow participants for up to 5.5 years to see how well the treatme…

This study is creating a French registry to collect information on children with Noonan Syndrome who are being treated with Norditropin®, a growth hormone. It aims to track their long-term growth, monitor safety, and understand how treatment affects their quality of life. The stu…

This study is testing a new medicine called concizumab to see if it can safely prevent bleeding episodes in people with haemophilia A or B who have developed inhibitors. Participants will give themselves a daily injection under the skin at home for up to seven years. The goal is …

This study is testing a new medicine called concizumab to see if it can safely prevent bleeding episodes in children under 12 who have hemophilia A or B. Participants will give themselves a daily injection under the skin for 2 to 4 years. The main goal is to see if this daily tre…

This study is testing a new, once-a-week growth hormone injection called somapacitan in children who are shorter than average. It includes kids born small, or with Turner syndrome, Noonan syndrome, or unexplained short stature. The main goals are to see if the treatment is safe a…

This 5-year study is testing whether adding a weekly injection called semaglutide to standard diabetes care can slow the progression of diabetic eye disease. About 1,500 adults with type 2 diabetes will receive either semaglutide or a placebo injection. Researchers will track cha…

This study compares a new weekly growth hormone injection (somapacitan) against the standard daily injection (Norditropin®) for children who were born small and remained short. Over 62 children will receive either treatment for 5 years to see if the weekly option works as well an…

This large study is testing whether a weekly injection called CagriSema can reduce serious heart problems like heart attacks and strokes in people who already have heart disease. About 7,100 participants aged 55+ with a history of heart issues will receive either the real injecti…

This study is testing whether a weekly injection called semaglutide can help adolescents with obesity maintain weight loss over the long term. All 500 participants, aged 12 to under 15, will receive the injection for at least three years. The goal is to see if the treatment helps…

This study is testing whether a daily injection called liraglutide, combined with lifestyle counseling, can help children aged 6 to 12 with obesity manage their weight. For 56 weeks, about 78 children will receive either the real medicine or a placebo (dummy) injection, and neith…

This study is observing 555 adults with obesity in Germany who are already prescribed the medication semaglutide (Wegovy) by their doctor. The goal is to collect real-world data over 12 months on how well the drug, combined with lifestyle changes, helps people lose weight and imp…

This study aims to monitor the safety and effectiveness of the weight-loss medication Wegovy in everyday medical practice in Japan. Over 1000 adults with obesity, who have already been prescribed Wegovy by their doctor, will be followed for two years. Researchers will track side …

This large, late-stage study is testing whether a new monthly injection called ziltivekimab can reduce the risk of major heart problems like heart attacks and strokes. It involves about 6,200 people who already have heart disease, chronic kidney disease, and signs of body-wide in…

This large, late-stage trial is investigating whether a pill called semaglutide, already used for diabetes, can slow the progression of early Alzheimer's disease. About 1,840 participants with mild memory problems will be randomly assigned to receive either the real medication or…

This study will monitor the long-term safety and effectiveness of a preventative treatment (Refixia/REBINYN) for males with hemophilia B. Over 4-9 years, researchers will track side effects, bleeding episodes, and how well the drug controls bleeding during surgery or injuries. Pa…

This early-stage study is testing a new injectable medicine called NNC0519-0130 for people with type 2 diabetes and excess weight. It will measure how the drug moves through the body and check for side effects in 20 Chinese men with overweight or obesity. Participants will receiv…

This study is testing a new weekly injection called CagriSema to see if it helps people with obesity lose weight and keep it off long-term. About 400 adults will receive either the real medicine or a placebo (dummy medicine) for two years, followed by a one-year extension phase. …

This study is testing whether a new investigational medicine called cagrilintide helps people with overweight or obesity lose weight and improve their health. About 300 adults will receive either cagrilintide or a placebo (dummy treatment) by random chance for about 18 months. Re…

This study is testing a new weekly injection called CagriSema to see how well it helps people with obesity lose weight. About 300 adults will receive either the real injection or a placebo (dummy medicine) for about a year and a half. The main goal is to measure how much body wei…

This study is testing whether an investigational medicine called cagrilintide helps people with type 2 diabetes and overweight or obesity lose weight and improve their health. About 330 participants will be randomly assigned to receive either the new medicine or a placebo for abo…

This study is testing a weekly injection called CagriSema to see how well it helps people with obesity lose weight and keep it off for the long term. About 600 participants will receive either the active medicine or a placebo (dummy injection) for over 3 years. Researchers will m…

This study follows males with moderate to severe hemophilia A who are already using Esperoct® to prevent bleeding episodes. Researchers will track how well the treatment works and monitor any side effects over 5-7 years of regular use. Participants continue their normal treatment…

This study continues testing an experimental medicine called NNC6019-0001 for people with a serious heart condition caused by protein buildup. It will follow 80 participants for up to 3 years to see how safe the medicine is long-term and whether it helps improve heart function an…

This large, late-stage trial is testing whether a pill called semaglutide, already used for diabetes, can slow the progression of early Alzheimer's disease. About 1,840 participants with mild memory problems will take either the real medicine or a placebo pill for over three year…

This study is observing how well the weekly weight-loss injection Wegovy works for Korean adults with obesity in everyday medical practice. About 500 participants will receive the treatment as prescribed by their doctor, and researchers will track their weight, body composition, …

This large international project aims to prevent childhood obesity by testing community-based programs that encourage healthy eating and physical activity. It will involve about 36,000 children aged 6-13 from disadvantaged urban areas across six countries. Researchers will measur…

This study is gathering feedback from 125 people with type 1 or type 2 diabetes who are already using the DuraTouch® injection device. Over 12 weeks, participants will rate how easy, convenient, and satisfying the device is to use in their daily lives. The goal is to understand t…

This study is testing whether weekly injections of an investigational drug called CagriSema can reduce pain from diabetic nerve damage. It will compare CagriSema to a placebo in 142 adults with type 2 diabetes who have had this specific nerve pain for at least 3 months. The main …

This study follows 96 people with moderate Parkinson's disease for up to two years to track how their symptoms change over time. Participants continue their regular medications while researchers monitor their movement abilities during both 'on' and 'off' medication periods. The s…

This study is collecting safety information from an existing European patient registry. It aims to monitor side effects in people with hemophilia A who are already being treated with the medication turoctocog alfa pegol. The study does not involve giving patients any new treatmen…

This study aims to better understand haemophilia in Asia-Pacific countries by collecting survey data from doctors, patient organizations, and people with haemophilia. It will measure how common the condition is, how many new cases occur, and what the care experience is like. No m…

This study aims to understand the safety of the weight-loss medication Wegovy during pregnancy. Researchers will follow about 728 pregnant women—some taking Wegovy and some not—to compare health outcomes for both mothers and their babies. The study will track infants through thei…

This study aims to monitor the long-term safety and effectiveness of Sogroya (somapacitan) in adults with growth hormone deficiency during routine clinical care. Researchers will follow 400 participants for 5-10 years, collecting data on side effects, health changes, and quality …

This study looks at existing health records to understand if taking the weight-loss medication Wegovy during pregnancy affects the health of mothers and babies. Researchers will compare about 1,100 pregnancies where women took Wegovy to pregnancies where they didn't. The goal is …

This is a survey study to learn about the real-world experiences of people using the injectable weight loss medication semaglutide. It will collect online responses from over 2,500 participants in four countries over 14 months. The goal is to understand their satisfaction, weight…

This study aims to learn about health data collection by observing 200 adults with overweight or obesity who are starting a weight management program. Participants will use their own smartphone, along with a provided smartwatch and scale, to share health information remotely for …